Establishing tomorrow's standard of care
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Our main activities include drug development, drug manufacturing and digital health investment.
Clinical trials
Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.
Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award
Your task is not to foresee the future, but to enable it.
History
For 40 years, we have been driven by the same commitment: bringing innovative solutions to patients
Our story began in 1979 when Dr. Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to establish Debiopharm, a company dedicated to in-licensing innovative compounds and developing them into medicines for out-licensing. Having launched this unique business model with a staff of only 2 people, today, Debiopharm’s 420 employees are now active in a variety of roles within drug development, drug manufacturing and investment in digital health and smart data start-ups.
Together with his son Thierry Mauvernay, they were able to build a team of dedicated professionals with a broad range of expertise. Debiopharm is now a group of three companies active in drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund).
Through corporate responsibility we aim to positively contribute to society and the environment
Each year Debiopharm co-organizes and presents two honors: the JCA-Mauvernay Award and the "Challenge Debiopharm-Inartis" Grant